Had owned this for many years, but unfortunately sold too early. Not a cheap stock, trading at about 25X earnings, but have done a very good job. They have a very strong market share in Canada. Also, they’ve done a very good job of bringing in other parts of the movie industry such as the Metropolitan Opera, hockey games, etc. They’ve diversified their viewership. There has been a very good flow of blockbuster movies. Has also done a very good job on the concessions side.

Trading at 6.5X earnings, so it is not expensive. Has a free cash flow yield of 13%. They have 2 main products. HIV which continues to grow and a Hepatitis C franchise. The revenue from the Hep C business is declining. He feels the stock is saying the Hep C is not going to generate any revenue for them, but there is still lots of revenue coming in. Also has some very interesting products in their pipeline which has not been taking into consideration. They have billions of dollars overseas, and can do lots of acquisitions. Dividend yield of 2.62%. (Analysts’ price target is $94.79.)

This has a great mobile franchise, and are growing their online brand globally. Great products. For a great brand name like this, you are only paying 25X earnings. Thinks earnings are going to accelerate into next year. Dividend yield of 1.42%. (Analysts’ price target is $61.97.)

This has sales, servicing as well as financing, and is a very good business in the long run. Old management made too many acquisitions and didn’t integrate them properly. Because of this, the stock collapsed. New management came in and are committed to making acquisitions, but only 2 or 3 a year. They are also trying to diversify out of BC and Alberta. Throws up about $50 million a year in free cash, and thinks they will be able to use that for acquisitions. Dividend yield of 1.72%. (Analysts’ price target is $24.25.)

This has a lot of different moving parts to this. The longer-term chart has been okay, but seems to be breaking down a little. Generally speaking, a lot of the metals can start the year off pretty good, so this company may bounce. However, the chart is looking a little tepid and it may be breaking down. He would like to see the current area break out before he bought into it.

Chart shows a series of higher highs and higher lows, but is a little bit iffy on the high side. We are still not in the new high area, and on the verge of pulling back a bit. He would give the chart a 6 out of 10. If you own, continue to hold.

The chart indicates that there is a little bit of support coming in, and it appears that it wants to bounce off that support. Support is at about $42, and you might very well see the stock return to the top end of the trading range. Probably not a bad buy if you like the fundamentals. He would be cautious once it gets to the $48 range. It looks like a trader right now.